---
document_datetime: 2023-09-21 18:24:05
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/celvapan-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: celvapan-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.3025701
conversion_datetime: 2025-12-15 19:32:39.359116
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                                                      |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|--------------------------------------------------------------|
| T/0031               | Transfer of Marketing Authorisation                                                                                                           | 05/11/2015                          | 30/11/2015                                     | SmPC, Labelling and PL           |                                                              |
| PSUSA/2280/ 201410   | Periodic Safety Update EU Single assessment - pandemic influenza vaccine (h1n1) (whole virion, inactivated, prepared in cell culture) product | 11/06/2015                          | n/a                                            |                                  | PRAC Recommendation - maintenance                            |
| R/0029               | Renewal of the marketing authorisation.                                                                                                       | 26/02/2015                          | 06/05/2015                                     | Annex II                         | Based on the review of available information, the CHMP is of |

<!-- image -->

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact Celvapan Procedural steps taken and scientific information after the authorisation 1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures. 2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

| PSUV/0027   | Periodic Safety Update                                                                                                                                                                                                                                                                                                     | 13/06/2014   | the opinion that the quality, safety and continues to be adequately and sufficiently and considers that the benefit/risk profile product continues to be favourable. The CHMP recommends that the renewal unlimited validity. n/a PRAC Recommendation - maintenance authorised   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0028      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                           | 26/05/2014   | 19/06/2014 PL                                                                                                                                                                                                                                                                    |
| IAIN/0026   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                             | 21/06/2013   | 19/06/2014 SmPC, Annex II and PL longer                                                                                                                                                                                                                                          |
| II/0024     | Change to analytical method used during the manufacture of the active substance. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Change (replacement) to a biological/immunological/ immunochemical test method or a method using a biological reagent for a biological AS product | 30/05/2013   | n/a no                                                                                                                                                                                                                                                                           |
| IB/0023     | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                      | 05/03/2013   | n/a                                                                                                                                                                                                                                                                              |
| IA/0022     | A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding                                                                                                                                                                    | 16/10/2012   | n/a                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|           | manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |               |                                         |                                                                             |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-----------------------------------------|-----------------------------------------------------------------------------|
| II/0019/G | This was an application for a group of variations. Update of sections 4.2, 4.6, 4.8 and 5.1 of the SmPC to reflect the results on immunogenicity and safety from the pandemic observational study 820901 and the paediatric study 820903. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to include minor amendments in the SmPC and Labelling. Furthermore, the PI is being brought in line with the latest QRD template version 8.1. Some of the obligations (Conditions to the Marketing Authorisation) have been deleted from the Annex II as fulfilled. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the product | 21/06/2012 | 26/07/2012 no | SmPC, Annex II, Labelling and PL longer | Please refer to the assessment report: Celvapan-H-982-II-19-G-AR authorised |
| IB/0020   | B.II.f.1.a.1 - Stability of FP - Reduction of the shelf life of the finished product - As packaged for sale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 18/06/2012 | 26/07/2012    | SmPC                                    |                                                                             |

<div style=\"page-break-after: always\"></div>

| IA/0021   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 15/05/2012    | n/a authorised                                                                                           |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|----------------------------------------------------------------------------------------------------------|
| IB/0018   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Extension of storage period of a biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 22/06/2011    | n/a SmPC, Annex II and PL                                                                                |
| II/0017/G | This was an application for a group of variations. Group of 5 type II variations (C.I.4) to update of sections 4.8 and 5.1 of the SmPC further to the evaluation of clinical follow-up measures (FUMs 30, 38, 39 & 40) and of the PSUR covering the period from 6 October 2009 to 30 September 2010 as requested by the CHMP. The section 4 of the PL has been updated accordingly. The MAH took the opportunity to correct mistakes in section 4.2 and 4.6 of the SmPC and to update the contact details for Latvia in the PL. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data C.I.4 - Variations related to significant modifications of product | 14/04/2011 no | 18/05/2011 SmPC, Annex II and PL Please refer to the assessment report: Celvapan-H-982-II-17-G-AR longer |

<div style=\"page-break-after: always\"></div>

|         | clinical or pharmacovigilance data C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |               |                              | authorised                                                     |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|------------------------------|----------------------------------------------------------------|
| SW/0014 | Switch from conditional to full Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 22/04/2010 | 12/08/2010    | SmPC, Annex II, Labelling    |                                                                |
| II/0013 | Update of section 4.8 of the SmPC to reflect safety data of SO2 028.4 (abridged report for post-dose 2 safety and immunogenicity data from paediatric H1N1 study 820903), S-PSUR 4 and preliminary data from observational study 820901. The Package Leaflet has been updated accordingly. In addition the MAH took this opportunity to update the PI to reflect safety data of SO2 027.2 (abridged report for post-dose 2 safety and immunogenicity data from adult H1N1 study 820902). Annex II has also been updated to reflect the current status of the specific obligations. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the product | 18/03/2010 | 05/07/2010 no | SmPC, Annex II and PL longer | Please refer to the assessment report: Celvapan-H-982-II-13-AR |
| II/0007 | Update of sections 4.2 and 5.1 of the SmPC based clinical study results (920903) with Celvapan containing 7.5µg H1N1 antigen of the A/H1N1/California/07/2009 influenza virus in infants,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 18/03/2010 | 05/07/2010    | SmPC and PL                  | Please refer to the assessment report: Celvapan-H-982-II-07-AR |

<div style=\"page-break-after: always\"></div>

|         | children and adolescent aged 6 months to 17 years. Section 3 of the PL has been updated accordingly. Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                    |            |               |                              | authorised                                                                                                                                                                                                                                                                                               |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0005 | Update of sections 4.2 and 5.1 of the SmPC based clinical study results (study 920902) with Celvapan containing 7.5µg H1N1 antigen of the A/H1N1/California/07/2009 influenza virus in adults and elderly. The PL has been updated accordingly. Update of Summary of Product Characteristics and Package Leaflet                                                                                         | 18/03/2010 | 05/07/2010    | SmPC and                     | PL Please refer to the assessment report: Celvapan-H-982-II-05-AR                                                                                                                                                                                                                                        |
| II/0012 | Update of section 4.8 of the SmPC based on the 2nd S-PSUR for Celvapan covering the period 17.11.09 - 14.12.09. Consequently the PL was updated. In addition the MAH took this opportunity to update Annex II to reflect the current status of the specific obligations and contact details of local representatives in the PL. Update of Summary of Product Characteristics and Package Leaflet product | 18/03/2010 | 30/03/2010 no | SmPC, Annex II and PL longer | Please refer to the scientific discussion: Celvapan-H-982-II-12-AR                                                                                                                                                                                                                                       |
| II/0008 | Update of the Detailed Description of the Pharmacovigilance System (DDPS) to reflect outsourcing of services to a CRO during a declared pandemic and additional Celvapan specific procedures. Consequently, Annex II has been updated with the new version number of the agreed DDPS.                                                                                                                    | 18/02/2010 | 30/03/2010    | Annex II                     | The DDPS has been updated to version 1.20-2-Celvapan to reflect the changes. Consequently, Annex II has been updated using the standard text including the new version number of the agreed DDPS. The CHMP considers that the Pharmacovigilance System as described by the MAH fulfils the requirements. |

<div style=\"page-break-after: always\"></div>

|         | Update of DDPS (Pharmacovigilance)                                                                                                                                                                                                                                                                                        |            |               |                       |                                                                         |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-----------------------|-------------------------------------------------------------------------|
| II/0010 | To introduce changes in the purification II process of the drug substance. Quality changes                                                                                                                                                                                                                                | 18/02/2010 | 05/03/2010    |                       | authorised                                                              |
| II/0011 | To introduce an alternative manufacturing site for formulation of the finished product. Quality changes                                                                                                                                                                                                                   | 21/01/2010 | 09/02/2010    | longer                |                                                                         |
| II/0009 | Update of sections 4.2, 4.4 and 4.8 of the SmPC to reflect safety information available with Celvapan containing the A/H1N1/California/07/2009 influenza virus in adults (including the elderly). Annex II and sections 2 and 4 of the PL have been updated accordingly. Update of Summary of Product Characteristics and | 17/12/2009 | 22/12/2009 no | SmPC, Annex II and PL | Please refer to the scientific discussion: Celvapan-H-982-II-09-AR      |
| II/0006 | Package Leaflet To update sections 4.8 of the SmPC to reflect safety results of H1N1 studies in children and in adults as requested by the CHMP. Annex II and the PL were updated accordingly. Update of Summary of Product Characteristics and Package Leaflet product                                                   | 22/10/2009 | 11/11/2009    | SmPC, Annex II and PL | Please refer to the Public assessment report. (Celvapan-H-982-II-06-AR) |
| II/0004 | To introduce an additional filing site for the Drug product                                                                                                                                                                                                                                                               | 22/10/2009 | 28/10/2009    |                       |                                                                         |

<div style=\"page-break-after: always\"></div>

|         | Quality changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |               |                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0003 | To increase the batch size of the final Drug Product. Quality changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 22/10/2009    | 28/10/2009                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| PU/0002 | The MAH applied to update the vaccine strain in Celvapan from H5N1 to the Pandemic strain H1N1 (A/California/7/2009 (H1N1)v). Pandemic Update                                                                                                                                                                                                                                                                                                                                                                                                                       | 01/10/2009    | 06/10/2009 SmPC, II, Labelling and PL              | Annex authorised                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0001 | Update of sections 4.6 and 5.3 of the SmPC to reflect results of two reproductive and developmental toxicology studies in the rat. The MAH took the opportunity to introduce corrections in the labelling and Annex II. The wording in Annex II regarding PSUR requirements during a pandemic was revised. The list of local representatives in the PL was updated for Cyprus, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Norway, Romania, Slovenia and Sweden. Update of Summary of Product Characteristics, Labelling and Package Leaflet product | 23/07/2009 no | 27/08/2009 SmPC, Annex II, Labelling and PL longer | Two rat studies were conducted to assess the effect of an H5N1 vaccine and vaccine-specific antibodies on reproduction and development. The responses to the vaccine and exposure of fetuses to specific antibodies in rats did not elicit vaccine-related harmful effects on mating performance or female fertility, embryo-foetal survival and pre- and post-natal development. The product information was updated to reflect this. |

Update of Summary of Product Characteristics, Labelling and Package Leaflet Medicinal product no longer authorised